Clinical Trial Update: Xeomin® and Gait Related Mobility After Stroke [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update shows Xeomin (onabotulinumtoxinA) being studied for improving gait-related mobility after stroke and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Stroke | Phase 4 | Status: RECRUITING